ERBB2 and breast carcinoma: Several investigations, i.e., Starch/polydopamine coated core–shell NPs [132], Bionized nanoferrite NPs/anti-HER2 antibody (BH NPs) [133], Tyramine-functionalized starch (Tyr-St)/tannic acid (TA)/phenolated-magnetic NPs (Fe3O4-PhOH NPs)/Dox [134], Hydroxychloroquine (HCQ)/Fmoc/hydroxyethyl starch (HES)/PTX [135], Polyethylenimine-β-cyclodextrin (roFPC)/Dox/hTERT siRNA [136], etc., have been further developed and investigated at in vitro settings to understand the efficacy in breast cancer therapy.